Clinical Research Directory
Browse clinical research sites, groups, and studies.
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
Sponsor: TargetCancer Foundation
Summary
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2020-10-01
Completion Date
2025-12
Last Updated
2024-08-09
Healthy Volunteers
No
Interventions
FoundationOne CDx and FoundationOne Liquid CDx
Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.
Locations (1)
TargetCancer Foundation
Cambridge, Massachusetts, United States